Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5582488 | 0.98 | PDE7A (0.42) | PDE7APDE7B | |
| SCHEMBL351324 | 0.81 | PDE7A (0.50) | PDE7APDE7B | |
| SCHEMBL551553 | 0.81 | PDE7A (0.50) | PDE7APDE7B | |
| SCHEMBL22422289 | 0.81 | PDE7A (0.50) | PDE7APDE7B | |
| SCHEMBL11491220 | 0.81 | PDE7A (0.50) | PDE7APDE7B | |
| SCHEMBL11870539 | 0.81 | PDE7A (0.50) | PDE7APDE7B | |
| SCHEMBL542497 | 0.78 | PDE7A (0.47) | PDE7APDE7B | |
| SCHEMBL630549 | 0.73 | CRBN (0.43) | PDE7APDE7B | |
| SCHEMBL2505773 | 0.70 | PDE7A (0.32) | PDE7A | |
| SCHEMBL23039345 | 0.70 | PDE7A (0.41) | PDE7APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| US-20050176703-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | PDE7A 998/4885PDE7B 1128/4885 |
| US-20050176703-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | PDE7A 998/4885PDE7B 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.